{"nctId":"NCT02896127","briefTitle":"Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis","startDateStruct":{"date":"2016-10-18","type":"ACTUAL"},"conditions":["Ankylosing Spondyloarthritis"],"count":458,"armGroups":[{"label":"Secukinumab","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Secukinumab","otherNames":["AIN457"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMale or non-pregnant, non-lactating female patients at least 18 years of age\n\nDiagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray or radiologist's report) fulfilling the Modified New York criteria for AS:\n\n* Active AS assessed by BASDAI ≥4 (0-10) at Baseline\n* Spinal pain as measured by BASDAI question #2 ≥ 4 cm (0-10 cm) at Baseline\n* Total back pain as measured by VAS ≥ 40 mm (0-100 mm) at Baseline Patients should have had inadequate response or failure to respond to at least 2 NSAIDs at an approved dose for a minimum of 4 weeks in total and a minimum of 2 weeks for each NSAID prior to randomization, or less than 4 weeks if therapy had to be withdrawn due to intolerance, toxicity or contraindications Patients who are regularly taking NSAIDs (including COX-1 or COX-2 inhibitors) as part of their AS therapy are required to be on a stable dose for at least 2 weeks before randomisation Patients who have been on a TNFα inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to randomization or have been intolerant to at least one administration of an anti-TNFα agent\n\nExclusion Criteria:\n\n* Chest X-ray or MRI with evidence of ongoing infectious or malignant process\n\n  * Patients taking high potency opioid analgesics\n  * Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor\n  * Pregnant or nursing (lactating) women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria)","description":"ASAS20 response is defined as an improvement of ≥20% and ≥1 units on a scale of 10 in at least three of the four ASAS main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"The Proportion of Participants Who Achieve an ASAS40 Response","description":"ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain\n\nThe number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in hsCRP Over Time","description":"hsCRP is measured as a marker of inflammation from blood samples during the study\n\nThe number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.78","spread":"22.919"},{"groupId":"OG001","value":"-0.79","spread":"20.023"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve an ASAS 5/6 at Week 16","description":"The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains\n\nThe number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With BASDAI Response at 16 Weeks","description":"The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS\n\nThe number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"22.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Short Form (36) - PCS Responders (Improvement of >= 2.5 Points) at Week 16","description":"The Physical Component Summary (PCS) SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions\n\nThe number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":null},{"groupId":"OG001","value":"61.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in ASQoL Score Over Time","description":"The Ankylosing Spondylitis Quality of Life (ASQoL) is an instrument to assess health-related quality of life among adult patients with Ankylosing Spondylitis.\n\nEach statement on the ASQoL is given a score of \"1\" or \"0\". A score of \"1\" is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"4.98"},{"groupId":"OG001","value":"-2.6","spread":"4.28"}]}]}]},{"type":"SECONDARY","title":"The Proportion of Patients Who Achieve an ASAS Partial Remission","description":"The The Assessment in SpondyloArthritis International Society (ASAS) partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10\n\nThe number analyzed for some of continuous outcome variables are the number of participants for whom the specific outcome data were available. Thus the number for these variables differs from the FAS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":453},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Hepatic function abnormal","Alanine aminotransferase increased"]}}}